Use the hyperlinks, where available to access additional clinical trial information.
A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma
Other Non-Commercial Sponsor
Eligible participants will receive treatment in two parts. In Part A, participants will undergo a biopsy, followed by one cycle (28 days) of treatment with AB-218, an orally available, small molecule inhibitor of mutated IDH1, and then a safe maximal resection (surgery) of the tumour. In Part B, following recovery from surgery, participants will receive up to 12 cycles of AB-218.